Availability Of Drug For Rare Diseases At Economical Prices Material Factor To Be Considered Before Restraining Via Interim Injunction: Delhi High Court
In a recent ruling, the Delhi High Court has addressed a significant intellectual property rights (IPR) dispute between F. Hoffmann-La Roche AG and Natco Pharma Limited regarding a patent for the drug Risdiplam. The drug is used to treat Spinal Muscular Atrophy (SMA), a rare disease. The court's decision primarily focused on accessibility of the drug at affordable prices and the validity of the patent held by F. Hoffmann-La Roche…
